AOD-9604

Clinical Trials

Weight Management

A modified fragment of human growth hormone (hGH 176-191) that stimulates fat metabolism without the growth-promoting effects of full GH.

Administration

Subcutaneous injection or oral

Dosage Range

250-500 mcg daily

Mechanism of Action

AOD-9604 mimics the lipolytic fragment of growth hormone, stimulating fat breakdown through beta-3 adrenergic receptor activation while inhibiting lipogenesis, without affecting blood sugar or growth.

Clinical Benefits

Stimulates fat breakdown (lipolysis)

Inhibits fat formation (lipogenesis)

No effect on blood sugar

No growth-promoting effects

Supports cartilage repair

Clinical Evidence

Phase II clinical trials demonstrated significant fat loss without adverse metabolic effects. TGA (Australia) approved as a food supplement. Additional studies show cartilage regeneration potential.

Side Effects

Injection site irritation

Mild headache

Temporary joint stiffness

Contraindications

Active cancer

Pregnancy

Severe liver disease

Related Peptides in Weight Management

Semaglutide

A GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and promotes significant weight loss with cardiovascular benefits.

Tirzepatide

A dual GIP/GLP-1 receptor agonist that delivers superior weight loss and metabolic improvements compared to single-target therapies.

MOTS-c

A mitochondrial-derived peptide that acts as an exercise mimetic, improving metabolic function and insulin sensitivity.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Peptide therapy should only be administered under the supervision of a qualified healthcare provider. Always consult your physician before starting any new treatment protocol.